A multi-institutional team developed a chimeric antigen receptor (CAR) T cell-based strategy for specifically targeting AML cells in patients who relapsed following other treatments. The team ...

Exicure, Inc. (Nasdaq: XCUR) today shared updates on its lead asset, GPC-100 (burixafor), a small molecule CXCR4 inhibitor. Exicure, Inc. ("Exicure") is planning for a clinical trial in Acute Myeloid ...

Omeros Corporation (Nasdaq: OMER) today announced the establishment of the Omeros Oncology Clinical Steering Committee to ...

A Winnipeg couple has temporarily relocated to Memphis, Tennessee, in search of lifesaving treatment for their 3-year-old son ...

The FDA granted a positive review for an acute myeloid leukemia drug trial, with initial dosing expected in 2025.

Omeros forms oncology committee to guide development of its AML therapy, which showed strong efficacy and safety in ...

Discover the latest findings on transplantation outcomes in Myelodysplastic Syndrome and Acute Myeloid Leukaemia from EBMT ...

Ziftomenib’s FDA application for relapsed/refractory NPM1-mutant acute myeloid leukemia is supported by data from the ...

One main goal of anti-cancer therapies is to kill tumor cells without affecting the surrounding normal cells. Therefore, many drugs are designed to target tumor-specific antigens, which are molecules ...